Brief: Xenetic Biosciences Inc - On April 26, Co Entered Exclusive Sublicense Agreement With CLS Therapeutics
27/04/2022 11:43
April 27 (Reuters) - Xenetic Biosciences Inc XBIO.O :
* XENETIC BIOSCIENCES INC - ON APRIL 26, CO ENTERED EXCLUSIVE SUBLICENSE
AGREEMENT WITH CLS THERAPEUTICS
* XENETIC BIOSCIENCES INC - PURSUANT TO DEAL CO RECEIVED EXCLUSIVE LICENSE,
UNDER
CERTAIN PATENT RIGHTS AND KNOW-HOW OWNED OR CONTROLLED BY CLS
* XENETIC BIOSCIENCES - CO RECEIVED PATENTS FROM CLS TO DEVELOP
PHARMACEUTICAL
PRODUCTS USING DNASE ENZYME FOR USE IN TREATMENT OF CANCER
Source text for Eikon: ID:
Further company coverage: XBIO.O
((Reuters.Briefs@thomsonreuters.com;))